Clinical Trial Update: Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

View source ↗

Summary

An observational study of Moderna's RSV vaccine candidate mRNA-1345 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Moderna mRNA-1345 vaccine

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Status: COMPLETED